For Immediate Release

Chicago, IL – August 25, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Procter & Gamble Co. (PG), Forest Laboratories (FRX), Bank of America Corp. (BAC), JPMorgan Chase & Co. (JPM) and Credit Suisse (CS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

P&G Finds Buyer for Drug Business

Warner Chilcott, a specialty drug maker, recently announced plans to acquire Procter & Gamble Co.’s (PG) prescription drug business for about $3 billion.

Last December, P&G had announced its intention to restrict making new

...

Warner Chilcott, a specialty drug maker, recently announced plans to acquire Procter & Gamble Co.’s (PG) prescription drug business for about $3 billion.

Last December, P&G had announced its intention to restrict making new investments in the pharmaceutical division and divest its interest in the healthcare brands. It decided to focus more on over-the-counter products such as Pepto Bismol, Prilosec, Vicks cough medicines and other personal care brands. Management stated that the pressure from generics was also one of the reasons for it to consider divestiture of this business.

Earlier in fiscal 2008, P&G sold its Folgers coffee business to J.M. Smucker Inc. (SJM) and added beauty and grooming businesses to its portfolio. The company’s prescription drugs division comprises products such as Actonel for osteoporosis (which generates more than $1 billion in revenue) and Enablex for the treatment of overactive bladder.

Warner Chilcott, which makes birth control,

...

Leo Pharma is establishing a Chinese affiliate to market Leo Pharma's portfolio of drugs for the treatment of the chronic skin disease psoriasis and other dermatological products. Leo Pharma's leading psoriasis brand, Daivobet, has just been approved by the Chinese authorities and can now be marketed in China, according to the company. Leo Pharma's new company in [...]

Zila, Inc. (NASD: ZILAD), a marketer and reseller of over-the-counter, non-prescription oral and dermatological products, recently reported financial results for its fiscal 2008 fourth quarter and full year ended July 31, 2008. Net revenues for the fourth quarter increased 14 percent to $11.9 million, compared with $10.4 million during the corresponding period one-year earlier. Net revenues for fiscal year 2008 climbed 57 percent to $45.1 million, compared with $28.8 million for fiscal 2007.

Supporting the gains in net revenues, sales of ViziLite® Plus posted a year-over-year increase of 46 percent to $3.9 million, representing the eighth consecutive quarter of revenue growth for the product line. ViziLite® Plus with TBlue® is the Zila’s flagship product for the early detection of oral abnormalities that could lead to cancer. ViziLite® Plus is an adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer.

Commenting on

...

Zila, Inc. (NASD: ZILAD), a marketer and reseller of over-the-counter, non-prescription oral and dermatological products, recently reported financial results for its fiscal 2008 fourth quarter and full year ended July 31, 2008. Net revenues for the fourth quarter increased 14 percent to $11.9 million, compared with $10.4 million during the corresponding period one-year earlier. Net revenues for fiscal year 2008 climbed 57 percent to $45.1 million, compared with $28.8 million for fiscal 2007.

Supporting the gains in net revenues, sales of ViziLite® Plus posted a year-over-year increase of 46 percent to $3.9 million, representing the eighth consecutive quarter of revenue growth for the product line. ViziLite® Plus with TBlue® is the Zila’s flagship product for the early detection of oral abnormalities that could lead to cancer. ViziLite® Plus is an adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer.

Commenting on

...

Reason for comment York Pharma have announced the acquisition of the sales and worldwide commercial rights to two dermatological products from the Belgian Pharmaceutical and Chemical Company Solvay for a total consideration of €28.5m.

The products are Flammazine® and Flammacerium®, both brands are established in Europe for the prevention of infection in burns and topical wounds. The agreement with Solvay entails the transfer of the brands, any IP and sales on a worldwide basis as well as an associated 5 year supply contract of finished product from Solvay.

These silver-based sulfadiazine (anti-bacterial) products are approved in 21 countries although sales of the product are concentrated in France, Germany, Belgium and Spain. York estimates that the global market for topical anti-infectives is valued around US$450million with the current sales of these products around the $17.2 million (£ 8.7 million) mark or a penetration of 3.8%.

To finance this acquisition, York has

...